Atara Biotherapeutics (ATRA) Gross Profit (2022 - 2026)
Atara Biotherapeutics' (ATRA) quarterly Gross Profit came in at $392000.0 in Q1 2026, down 99.5% YoY from $77.7 million in Q1 2025, and down 73.71% on a QoQ basis from $1.5 million in Q4 2025.
Atara Biotherapeutics (ATRA) Gross Profit (2022 - 2026) Analysis & Trends
Atara Biotherapeutics (ATRA) has 5 years of Gross Profit data on file, last reported at $392000.0 in Q1 2026.
- Quarterly Gross Profit fell 99.5% year-over-year to $392000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $22.2 million (down 86.12% YoY) and the FY2025 annual result came in at $99.6 million, down 7.76% from the prior year.
- Gross Profit retreated to $392000.0 in Q1 2026, from $1.5 million in the prior quarter.
- In the past five years, Gross Profit ranged from a high of $77.7 million in Q1 2025 to a low of -$6.2 million in Q4 2023.
- A 5-year average of $16.1 million and a median of $3.9 million in 2022 frame the typical range for Gross Profit.
- Annual changes were most pronounced in 2023 — Gross Profit plunged 448.0% — and 2024, when it jumped 5576.97%.
- Tracing ATRA's Gross Profit over 5 years: stood at $1.8 million in 2022, then sank by 448.0% to -$6.2 million in 2023, then soared by 520.71% to $26.0 million in 2024, then slumped by 94.26% to $1.5 million in 2025, then tumbled by 73.71% to $392000.0 in 2026.
- The last three Gross Profit figures came in at $392000.0 (Q1 2026), $1.5 million (Q4 2025), and $3.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Atara Biotherapeutics | 141.08 Mn | 124.53 Mn | 439,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 439,000.00 |
| Jun 30, 2026 | 439,000.00 |
| Mar 31, 2026 | 392,000.00 |
| Mar 31, 2026 | 392,000.00 |
| Dec 31, 2025 | 1.49 Mn |
| Dec 31, 2025 | 1.49 Mn |
| Sep 30, 2025 | 3.34 Mn |
| Sep 30, 2025 | 3.34 Mn |
| Jun 30, 2025 | 17.02 Mn |
| Jun 30, 2025 | 17.02 Mn |
| Mar 31, 2025 | 77.71 Mn |
| Mar 31, 2025 | 77.71 Mn |
| Dec 31, 2024 | 25.96 Mn |
| Dec 31, 2024 | 25.96 Mn |
| Sep 30, 2024 | 32.59 Mn |
| Sep 30, 2024 | 32.59 Mn |
| Jun 30, 2024 | 24.01 Mn |
| Jun 30, 2024 | 24.01 Mn |
| Mar 31, 2024 | 25.37 Mn |
| Mar 31, 2024 | 25.37 Mn |